Last updated: 2026-10-16 21:02:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Allogene Therapeutics, Inc. (ALLO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.31, with a market capitalization of $449.14M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.04 to $4.46. This page covers its latest market performance, valuation, price trends and company information.
$449.14M | |
$1.34 | |
$55.00 | |
$0.86 | |
$1.34 | |
4.16M | |
5.67M | |
-- | |
$4.46 | |
$1.04 | |
-- | |
-- |
Allogene Therapeutics, Inc. (ALLO) is trading at $1.33 in after-hours trading as of 2026-10-16 20:37:00, down 1.12% ($0.02) from the regular-session close of $1.34.
After-hours trading shows how investors are pricing ALLO after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Allogene Therapeutics, Inc. (ALLO) moved from $1.43 to $1.31, representing a decline of 8.74% ($0.13).
The stock traded between $1.22 and $1.48 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 6.51 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 7.7%
ALLO is currently trading at $1.31, placing it 7.7% of the way from its 52-week low of $1.04 to its 52-week high of $4.46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 152 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Allogene Therapeutics, Inc. (ALLO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.